← Leaderboards
B. Kim Lee Sim
Entremed, Inc.
$24,806,815
Attributed
$24,806,815
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,806,815 · 16
By mechanism
R43$7,257,595 · 12
U01$5,933,702 · 1
R44$5,861,050 · 2
R01$5,754,468 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesImmunogenicityProtective EfficacyAntigensProductionClinical TrialsDoseAttenuatedPlasmodium FalciparumSafetyMalariaAntibodiesAfricaImmunizationSporozoitesVaccine CandidateFalciparum MalariaCulicidaeChildCyclic GmpProteinsGenerationsLicensingMalaria Vaccines
Grant awards (40)
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,012,212
U01 · FY2025 · AI · contact PI
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage$999,150
R44 · FY2025 · AI · contact PI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,083,506
U01 · FY2024 · AI · contact PI
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage$998,971
R44 · FY2024 · AI · contact PI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,243,700
U01 · FY2023 · AI · contact PI
A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage$999,880
R44 · FY2023 · AI · contact PI
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine$300,000
R43 · FY2023 · AI · contact PI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,279,157
U01 · FY2022 · AI · contact PI
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine$300,000
R43 · FY2022 · AI · contact PI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,315,127
U01 · FY2021 · AI · contact PI
Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers$293,842
R43 · FY2017 · AI · contact PI
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive$1,096,039
R01 · FY2016 · AI · contact PI
Live Attenuated Oral Typhoid-Shigellosis Vaccine$301,810
R43 · FY2016 · AI · contact PI
Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers$297,487
R43 · FY2016 · AI · contact PI
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive$1,083,123
R01 · FY2015 · AI · contact PI
Live Attenuated Oral Typhoid-Shigellosis Vaccine$307,387
R43 · FY2015 · AI · contact PI
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive$1,100,257
R01 · FY2014 · AI · contact PI
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive$1,063,088
R01 · FY2013 · AI · contact PI
Multi-ligand merozoite invasion blocking malaria vaccine$300,000
R43 · FY2013 · AI · contact PI
Multi-stage multi-antigen Vaccine for interrupting Malaria Transmission$300,000
R43 · FY2013 · AI · contact PI
Immunizing Against Malaria by Inducing Both Protective Antibodies and CD8 T Cells$300,000
R43 · FY2013 · AI · contact PI
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive$1,411,961
R01 · FY2012 · AI · contact PI
Plasmodium vivax recombinant CS protein vaccine for malaria$863,049
R44 · FY2012 · AI · contact PI
Immunizing Against Malaria by Inducing Both Protective Antibodies and CD8 T Cells$300,000
R43 · FY2012 · AI · contact PI
Multi-ligand merozoite invasion blocking malaria vaccine$300,000
R43 · FY2012 · AI · contact PI
Multi-stage multi-antigen Vaccine for interrupting Malaria Transmission$300,000
R43 · FY2012 · AI · contact PI
Plasmodium vivax recombinant CS protein vaccine for malaria$1,000,000
R44 · FY2011 · AI · contact PI
Live Attenuated Oral Anthrax Vaccine$299,996
R43 · FY2011 · AI · contact PI
Plasmodium vivax recombinant CS protein vaccine for malaria$1,000,000
R44 · FY2010 · AI · contact PI
Live Attenuated Oral Anthrax Vaccine$299,997
R43 · FY2010 · AI · contact PI
Recombinant Plasodium falciparum CelTOS vaccine$292,665
R43 · FY2009 · AI · contact PI
Recombinant Plasodium falciparum CelTOS vaccine$299,998
R43 · FY2008 · AI · contact PI
Plasmodium vivax recombinant CS protein vaccine$297,321
R43 · FY2006 · AI · contact PI
A SARS-CoV Spike Protein Vaccine$362,894
R43 · FY2005 · AI
Plasmodium vivax recombinant CS protein vaccine$299,613
R43 · FY2005 · AI
A Tetravalent Dengue Recombinanat Protein Vaccine$297,860
R43 · FY2005 · AI
A SARS-CoV Spike Protein Vaccine$306,908
R43 · FY2004 · AI
A Tetravalent Dengue Recombinanat Protein Vaccine$299,817
R43 · FY2004 · AI
RECOMBINANT MALARIA INVASION LIGAND PROTEIN VACCINE$300,000
R43 · FY2001 · AI
RECOMBINANT MALARIA INVASION LIGAND PROTEIN VACCINE$300,000
R43 · FY2000 · AI